These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

977 related items for PubMed ID: 33142417

  • 1. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
    Luo G, Ma Y, Liang X, Xie G, Luo Y, Zha D, Wang S, Yu L, Zheng X, Wu W, Zhang C.
    Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
    [Abstract] [Full Text] [Related]

  • 2. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Wang L, Liu X, Duan Y, Li X, Zhao B, Wang C, Xiao Z, Zheng P, Tang Q, Zhu W.
    Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
    [Abstract] [Full Text] [Related]

  • 3. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M, Kassab AE, Zaher AF, Mahmoud Z.
    Anticancer Agents Med Chem; 2019 Jul; 19(11):1368-1381. PubMed ID: 31038080
    [Abstract] [Full Text] [Related]

  • 4. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF, Bayoumi AH, El-Morsy AM, Sobhy M, Hagras M.
    Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity.
    Ali GME, Ibrahim DA, Elmetwali AM, Ismail NSM.
    Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722
    [Abstract] [Full Text] [Related]

  • 6. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W, Wang W, Xu S, Wang J, Tang Q, Wu C, Zhao Y, Zheng P.
    Bioorg Med Chem; 2016 Apr 15; 24(8):1749-56. PubMed ID: 26964675
    [Abstract] [Full Text] [Related]

  • 7. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB, Mehany ABM, Abdellatif KRA.
    Anticancer Agents Med Chem; 2017 Apr 15; 17(10):1389-1400. PubMed ID: 28270084
    [Abstract] [Full Text] [Related]

  • 8. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX, Liu X, Xu S, Tang Q, Duan Y, Xiao Z, Zhi J, Jiang L, Zheng P, Zhu W.
    Eur J Med Chem; 2017 Dec 01; 141():538-551. PubMed ID: 29107421
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction.
    Nan X, Zhang J, Li HJ, Wu R, Fang SB, Zhang ZZ, Wu YC.
    Eur J Med Chem; 2020 Aug 15; 200():112470. PubMed ID: 32505087
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X, Bao G, Wang L, Cheng M, Zhao M, Zhao S, Zhou H, Gong P.
    Bioorg Med Chem; 2016 Mar 15; 24(6):1331-45. PubMed ID: 26897090
    [Abstract] [Full Text] [Related]

  • 11. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
    Li J, Li J, Zhang J, Shi J, Ding S, Liu Y, Chen Y, Liu J.
    Anticancer Agents Med Chem; 2020 Mar 15; 20(5):559-570. PubMed ID: 31893997
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
    Wang Z, Shi J, Zhu X, Zhao W, Gong Y, Hao X, Hou Y, Liu Y, Ding S, Liu J, Chen Y.
    Bioorg Chem; 2020 Dec 15; 105():104371. PubMed ID: 33075664
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, antineoplastic activity of new pyrazolo[3,4-d]pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME prediction.
    Nemr MTM, Elshewy A, Ibrahim ML, El Kerdawy AM, Halim PA.
    Bioorg Chem; 2024 Sep 15; 150():107566. PubMed ID: 38896936
    [Abstract] [Full Text] [Related]

  • 14. Design, synthesis, and in vitro antiproliferative and kinase inhibitory effects of pyrimidinylpyrazole derivatives terminating with arylsulfonamido or cyclic sulfamide substituents.
    Gamal El-Din MM, El-Gamal MI, Abdel-Maksoud MS, Yoo KH, Baek D, Choi J, Lee H, Oh CH.
    J Enzyme Inhib Med Chem; 2016 Sep 15; 31(sup2):111-122. PubMed ID: 27255180
    [Abstract] [Full Text] [Related]

  • 15. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
    Nan X, Li HJ, Fang SB, Li QY, Wu YC.
    Eur J Med Chem; 2020 May 01; 193():112241. PubMed ID: 32200199
    [Abstract] [Full Text] [Related]

  • 16. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM, AboulWafa OM, Baghdadi HH, Abd El Razik HA, Sedra SMY, Shamaa MM.
    Bioorg Chem; 2021 Oct 01; 115():105208. PubMed ID: 34365057
    [Abstract] [Full Text] [Related]

  • 17. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF, El-Kalaawy AM, Abdel Latif NS, Rashed LA, Philoppes JN.
    Eur J Med Chem; 2021 Mar 15; 214():113222. PubMed ID: 33545637
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and bioevaluation study of novel N-methylpicolinamide and thienopyrimidine derivatives as selectivity c-Met kinase inhibitors.
    Wang L, Xu S, Chen X, Liu X, Duan Y, Kong D, Zhao D, Zheng P, Tang Q, Zhu W.
    Bioorg Med Chem; 2018 Jan 01; 26(1):245-256. PubMed ID: 29203143
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers.
    Gaber AA, Bayoumi AH, El-Morsy AM, Sherbiny FF, Mehany ABM, Eissa IH.
    Bioorg Chem; 2018 Oct 01; 80():375-395. PubMed ID: 29986185
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis and biological evaluation of novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide derivatives as potential c-Met kinase inhibitors.
    Liu J, Gong Y, Shi J, Hao X, Wang Y, Zhou Y, Hou Y, Liu Y, Ding S, Chen Y.
    Eur J Med Chem; 2020 May 15; 194():112244. PubMed ID: 32224380
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.